High neutralizing antibody titer in intensive care unit patients with COVID-19
ABSTRACTCoronavirus disease 2019 (COVID-19) has a wide spectrum of disease severity from mild upper respiratory symptoms to respiratory failure. The role of neutralizing antibody (NAb) response in disease progression remains elusive. This study determined the seroprevalence of 733 non-COVID-19 indiv...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-01-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2020.1791738 |
| _version_ | 1827320685867827200 |
|---|---|
| author | Li Liu Kelvin Kai-Wang To Kwok-Hung Chan Yik-Chun Wong Runhong Zhou Ka-Yi Kwan Carol Ho-Yan Fong Lin-Lei Chen Charlotte Yee-Ki Choi Lu Lu Owen Tak-Yin Tsang Wai-Shing Leung Wing-Kin To Ivan Fan-Ngai Hung Kwok-Yung Yuen Zhiwei Chen |
| author_facet | Li Liu Kelvin Kai-Wang To Kwok-Hung Chan Yik-Chun Wong Runhong Zhou Ka-Yi Kwan Carol Ho-Yan Fong Lin-Lei Chen Charlotte Yee-Ki Choi Lu Lu Owen Tak-Yin Tsang Wai-Shing Leung Wing-Kin To Ivan Fan-Ngai Hung Kwok-Yung Yuen Zhiwei Chen |
| author_sort | Li Liu |
| collection | DOAJ |
| description | ABSTRACTCoronavirus disease 2019 (COVID-19) has a wide spectrum of disease severity from mild upper respiratory symptoms to respiratory failure. The role of neutralizing antibody (NAb) response in disease progression remains elusive. This study determined the seroprevalence of 733 non-COVID-19 individuals from April 2018 to February 2020 in the Hong Kong Special Administrative Region and compared the neutralizing antibody (NAb) responses of eight COVID-19 patients admitted to the intensive care unit (ICU) with those of 42 patients not admitted to the ICU. We found that NAb against SARS-CoV-2 was not detectable in any of the anonymous serum specimens from the 733 non-COVID-19 individuals. The peak serum geometric mean NAb titer was significantly higher among the eight ICU patients than the 42 non-ICU patients (7280 [95% confidence interval (CI) 1468-36099]) vs (671 [95% CI, 368-1223]). Furthermore, NAb titer increased significantly at earlier infection stages among ICU patients than among non-ICU patients. The median number of days to reach the peak Nab titers after symptoms onset was shorter among the ICU patients (17.6) than that of the non-ICU patients (20.1). Multivariate analysis showed that oxygen requirement and fever during admission were the only clinical factors independently associated with higher NAb titers. Our data suggested that SARS-CoV-2 was unlikely to have silently spread before the COVID-19 emergence in Hong Kong. ICU patients had an accelerated and augmented NAb response compared to non-ICU patients, which was associated with disease severity. Further studies are required to understand the relationship between high NAb response and disease severity. |
| first_indexed | 2024-03-07T17:23:51Z |
| format | Article |
| id | doaj.art-3efabe15847a40bbb810a09d99037efc |
| institution | Directory Open Access Journal |
| issn | 2222-1751 |
| language | English |
| last_indexed | 2024-04-25T00:51:31Z |
| publishDate | 2020-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj.art-3efabe15847a40bbb810a09d99037efc2024-03-11T16:04:24ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512020-01-01911664167010.1080/22221751.2020.1791738High neutralizing antibody titer in intensive care unit patients with COVID-19Li Liu0Kelvin Kai-Wang To1Kwok-Hung Chan2Yik-Chun Wong3Runhong Zhou4Ka-Yi Kwan5Carol Ho-Yan Fong6Lin-Lei Chen7Charlotte Yee-Ki Choi8Lu Lu9Owen Tak-Yin Tsang10Wai-Shing Leung11Wing-Kin To12Ivan Fan-Ngai Hung13Kwok-Yung Yuen14Zhiwei Chen15AIDS Institute, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaState Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaState Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaAIDS Institute, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaAIDS Institute, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaAIDS Institute, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaState Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaState Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaState Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaState Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaDepartment of Medicine and Geriatrics, Princess Margaret Hospital, Hong Kong, Hong Kong Special Administrative Region, People’s Republic of ChinaDepartment of Medicine and Geriatrics, Princess Margaret Hospital, Hong Kong, Hong Kong Special Administrative Region, People’s Republic of ChinaDepartment of Pathology, Princess Margaret Hospital, Hong Kong, Hong Kong Special Administrative Region, People’s Republic of ChinaDepartment of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, People’s Republic of ChinaState Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaAIDS Institute, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaABSTRACTCoronavirus disease 2019 (COVID-19) has a wide spectrum of disease severity from mild upper respiratory symptoms to respiratory failure. The role of neutralizing antibody (NAb) response in disease progression remains elusive. This study determined the seroprevalence of 733 non-COVID-19 individuals from April 2018 to February 2020 in the Hong Kong Special Administrative Region and compared the neutralizing antibody (NAb) responses of eight COVID-19 patients admitted to the intensive care unit (ICU) with those of 42 patients not admitted to the ICU. We found that NAb against SARS-CoV-2 was not detectable in any of the anonymous serum specimens from the 733 non-COVID-19 individuals. The peak serum geometric mean NAb titer was significantly higher among the eight ICU patients than the 42 non-ICU patients (7280 [95% confidence interval (CI) 1468-36099]) vs (671 [95% CI, 368-1223]). Furthermore, NAb titer increased significantly at earlier infection stages among ICU patients than among non-ICU patients. The median number of days to reach the peak Nab titers after symptoms onset was shorter among the ICU patients (17.6) than that of the non-ICU patients (20.1). Multivariate analysis showed that oxygen requirement and fever during admission were the only clinical factors independently associated with higher NAb titers. Our data suggested that SARS-CoV-2 was unlikely to have silently spread before the COVID-19 emergence in Hong Kong. ICU patients had an accelerated and augmented NAb response compared to non-ICU patients, which was associated with disease severity. Further studies are required to understand the relationship between high NAb response and disease severity.https://www.tandfonline.com/doi/10.1080/22221751.2020.1791738COVID19SARS-CoV-2neutralizing antibodydisease severityICU patient |
| spellingShingle | Li Liu Kelvin Kai-Wang To Kwok-Hung Chan Yik-Chun Wong Runhong Zhou Ka-Yi Kwan Carol Ho-Yan Fong Lin-Lei Chen Charlotte Yee-Ki Choi Lu Lu Owen Tak-Yin Tsang Wai-Shing Leung Wing-Kin To Ivan Fan-Ngai Hung Kwok-Yung Yuen Zhiwei Chen High neutralizing antibody titer in intensive care unit patients with COVID-19 Emerging Microbes and Infections COVID19 SARS-CoV-2 neutralizing antibody disease severity ICU patient |
| title | High neutralizing antibody titer in intensive care unit patients with COVID-19 |
| title_full | High neutralizing antibody titer in intensive care unit patients with COVID-19 |
| title_fullStr | High neutralizing antibody titer in intensive care unit patients with COVID-19 |
| title_full_unstemmed | High neutralizing antibody titer in intensive care unit patients with COVID-19 |
| title_short | High neutralizing antibody titer in intensive care unit patients with COVID-19 |
| title_sort | high neutralizing antibody titer in intensive care unit patients with covid 19 |
| topic | COVID19 SARS-CoV-2 neutralizing antibody disease severity ICU patient |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2020.1791738 |
| work_keys_str_mv | AT liliu highneutralizingantibodytiterinintensivecareunitpatientswithcovid19 AT kelvinkaiwangto highneutralizingantibodytiterinintensivecareunitpatientswithcovid19 AT kwokhungchan highneutralizingantibodytiterinintensivecareunitpatientswithcovid19 AT yikchunwong highneutralizingantibodytiterinintensivecareunitpatientswithcovid19 AT runhongzhou highneutralizingantibodytiterinintensivecareunitpatientswithcovid19 AT kayikwan highneutralizingantibodytiterinintensivecareunitpatientswithcovid19 AT carolhoyanfong highneutralizingantibodytiterinintensivecareunitpatientswithcovid19 AT linleichen highneutralizingantibodytiterinintensivecareunitpatientswithcovid19 AT charlotteyeekichoi highneutralizingantibodytiterinintensivecareunitpatientswithcovid19 AT lulu highneutralizingantibodytiterinintensivecareunitpatientswithcovid19 AT owentakyintsang highneutralizingantibodytiterinintensivecareunitpatientswithcovid19 AT waishingleung highneutralizingantibodytiterinintensivecareunitpatientswithcovid19 AT wingkinto highneutralizingantibodytiterinintensivecareunitpatientswithcovid19 AT ivanfanngaihung highneutralizingantibodytiterinintensivecareunitpatientswithcovid19 AT kwokyungyuen highneutralizingantibodytiterinintensivecareunitpatientswithcovid19 AT zhiweichen highneutralizingantibodytiterinintensivecareunitpatientswithcovid19 |